Subtype
Malignant Infratentorial Neoplasm
CI-CAN-00007999Explore in graph →
99 active trials7 evidence items
- NCIt
- C4966
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007999Explore in graph →
Clinical trials
302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | withdrawn | — | 0 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies | withdrawn | Phase 1 | 0 | Jeffrey TreiberOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | withdrawn | Phase 1 | 0 | Y-mAbs TherapeuticsINDUSTRY | 0 | Jun 26, 2023 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors | withdrawn | N/A | 0 | Sue O'DorisioOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | withdrawn | Phase 1 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials